Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Benralizumab · Fasenra, BIW-8405

Monoclonal antibody · Kills target cells, directed at IL-5 receptor alpha (IL5RA) · developed by Astrazeneca

Approved FDA, Nov 2017

AZN Developer

1 Registered trials

What is Benralizumab?

Benralizumab is a humanized afucosylated monoclonal antibody that binds the alpha subunit of the IL-5 receptor on eosinophils and basophils. The absence of fucose in its Fc domain enhances binding to FcγRIII receptors on NK cells, triggering antibody-dependent cell-mediated cytotoxicity and eosinophil apoptosis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Fasenra, BIW-8405, MEDI-563
Drug type: Monoclonal antibody
Targets: IL-5 receptor alpha (IL5RA), FcγRIII receptor (FCGR3A) (secondary target)
Mechanism: Kills target cells, directed at IL-5 receptor alpha (IL5RA)
Pathways: antibody-dependent cell-mediated cytotoxicity (ADCC), eosinophil apoptosis
Therapy area: Immunology, Respiratory
Developer: Astrazeneca Ab (AZN)
FDA status: Approved as Fasenra (November 14, 2017), BLA761070 · FDA label
UNII: 71492GE1FX

✅ FDA-approved uses

Severe asthma with eosinophilic phenotype
Eosinophilic granulomatosis with polyangiitis (EGPA)
Hypereosinophilic syndrome (HES)

From the indications section of the FDA label (version of May 13, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05692180	Phase 3	Asthma	Active not recruiting	AZN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Asthma

More from Astrazeneca

Acalabrutinib FDA approved Anifrolumab FDA approved Camizestrant FDA approved Durvalumab FDA approved Olaparib FDA approved Tremelimumab FDA approved Actinium Ac 225 FPI-2068 Phase 1 Adavosertib Phase 2 AZD0240 Phase 1 AZD4144 Phase 1 AZD4916 Phase 1 AZD5492 Phase 1/2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the AZN page.

Follow AZN, the company behind Benralizumab

See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AZN catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z